Q-omics provides the consensus-scored SLC5A9 profile across patient tissues and cancer cell-line models. SLC5A9 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, SLC5A9 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, SLC5A9 protein abundance shows 19,653 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, LUAD, and LSCC as cancer lineages where SLC5A9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC5A9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC5A9 survival associations across molecular data types. SLC5A9 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC5A9 RNA expression–survival associations across cancer types. High SLC5A9 expression shows unfavorable associations in LUSC, LGG, UVM and LIHC, but favorable associations in HNSC and READ. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for SLC5A9 RNA expression.
This table summarizes SLC5A9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC5A9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC5A9 shows lower tumor expression in LUAD, KICH, LUSC, HNSC and BRCA and higher tumor expression in KIRC. The LUAD box plot shows higher SLC5A9 RNA expression in normal versus tumor tissue (log2 FC = −2.600, t-test p < 0.001).
This table shows molecular features associated with SLC5A9 in patient tissues and cancer cell lines. In patient samples, SLC5A9 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC5A9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
